Dai­ichi Sankyo launch­es glob­al R&D re­struc­tur­ing, look­ing to slash costs in an over­haul

You can add Japan’s Dai­ichi Sankyo to the list of phar­ma com­pa­nies re­struc­tur­ing their R&D or­ga­ni­za­tions.

Like Take­da be­fore it and a whole line­up of US and Eu­ro­pean phar­mas, Dai­ichi Sankyo is shut­ter­ing a re­search fa­cil­i­ty in In­dia and ax­ing 170 staffers. And the com­pa­ny says it is in the process of slash­ing costs around the world as it frees up cash.

In a state­ment, the com­pa­ny not­ed:

Dai­ichi Sankyo is re­view­ing its glob­al R&D sys­tem with the aim of de­creas­ing R&D op­er­a­tions costs and re­dis­trib­ut­ing re­sources to the fur­ther de­vel­op­ment of its R&D pipeline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.